Combination chemotherapy (cyclophosphamide, doxorubicin, and vincristine with continuous-infusion cisplatin and etoposide) and radiotherapy with stem cell support can be beneficial for adolescents and adults with estheisoneuroblastoma

Cancer

Volumn 101, Issue 6, 2004, Pages 1437-1444

  Mishima, Yuko ^a   Nagasaki, Eijiro ^a   Terui, Yasuhito ^a   Irie, Tetsuya ^a   Takahashi, Shunji ^a   Ito, Yoshinori ^a   Oguchi, Masahiko ^a   Kawabata, Kazuyoshi ^a   Kamata, Shinetsu ^a   Hatake, Kiyohiko ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Combined chemotherapy and radiotherapy; Esthesioneuroblastoma; Peripheral blood stem cell transplantation; Toxicity

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADOLESCENT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; ESTHESIONEUROBLASTOMA; FEMALE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; ILEUS; INAPPROPRIATE VASOPRESSIN SECRETION; INFECTION; KIDNEY TUBULE DISORDER; MALE; METABOLIC ALKALOSIS; ONSET AGE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL TIME; TETANY; TREATMENT INDICATION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTHESIONEUROBLASTOMA, OLFACTORY; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NOSE NEOPLASMS; RETROSPECTIVE STUDIES; VINCRISTINE;

EID: 4444375233     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20471     Document Type: Article

References (27)

1. Bernard JL, Bernard-Couteret E, Coste D, et al. Childhood cancer incidence in the south-east of France. A report of the Provence-Alpes-Cote d'Azur and Corsica Regions Pediatric Cancer Registry, 1984-1991. Eur J Cancer. 1993;29A:2284-2291.
2. Kumar M, Fallen RJ, Hill JS, Davis MM. Esthesioneuroblastoma in children. J Pediatr Hematol Oncol. 2002;24:482-487.
3. Chao KS, Kaplan C, Simpson JR, et al. Esthesioneuroblastoma: the impact of treatment modality. Head Neck. 2001; 23:749-757.
4. Elkon D, Hightower SI, Lim ML, et al. Esthesioneuroblastoma. Cancer. 1979;44:1087-1094.
5. Spaulding CA, Kranyak MS, Constable WC, Stewart FM. Esthesioneuroblastoma: a comparison of two treatment eras. Int J Radiat Oncol Biol Phys. 1988;15:581-590.
6. Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future? Laryngoscope. 2003;113: 502-507.
7. Bradley PJ, Jones NS, Robertson I. Diagnosis and management of esthesioneuroblastoma. Curr Opin Otolaryngol Head Neck Surg. 2003;11:112-118.
8. Theilgaard SA, Buchwald C, Ingeholm P, et al. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 2003; 123;433-439.
9. Dulguerov P, Allai AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2:683-690.
10. Jekunen AP, Kairemo KJ, Lehtonen HP, Kajanti MJ. Treatment of olfactory neuroblastoma. A report of 11 cases. Am J Clin Oncol. 1996;19:375-378.
11. Eich HT, Staar S, Micke O, et al. Radiotherapy of esthesioneuroblastoma. Int J Radiat Oncol Biol Phys. 2001;49:155-160.
12. Gruber G, Laedrach K, Baumert B, et al. Esthesioneuroblastoma: irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys. 2002;54:486-491.
13. Hwang SK, Paek SH, Kim DG, et al. Olfactory neuroblastomas: survival rate and prognostic factor. J Neurooncol. 2002; 59:217-226.
14. Resto VA, Eisele DW, Forastiere A, et al. Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck. 2000;22: 550-558.
15. Argiris A, Dutra J, Tseke P, Haines K. Esthesioneuroblastoma: the Northwestern University experience. Laryngoscope. 2003;113:155-160.
16. Chamberlain MC. Treatment of intracranial metastatic esthesioneuroblastoma. Cancer. 2002;95:243-248.
17. McElroy EA Jr., Buckner JC, Lewis JE. Chemotherapy for advanced esthesioneuroblastoma: the Mayo Clinic experience. Neurosurgery. 1998;42:1023-1027; discussion, 1027-1028.
18. Polin RS, Sheehan JP, Chenelle AG, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998;42:1029-1037.
19. Nguyen QA, Villabianca JG, Siegel SE, Crockett DM. Esthesioneuroblastoma in the pediatric age-group: the role of chemotherapy and autologous bone marrow transplantation. Int J Pediatr Otorhinolaryngol. 1996;37:45-52.
20. Eich HT, Hero B, Staar S, et al. Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in Stage C esthesioneuroblastoma. Strahlenther Onkol. 2003;179:233-240.
21. Fitzek MM, Thornton AF, Varvares M, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94:2623-2634.
22. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37:1571-1576.
23. Sheehan JM, Sheehan JP, Jane JA Sr., Polin RS. Chemotherapy for esthesioneuroblastomas. Neurosurg Clin North Am. 2000;11:693-701.
24. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for Stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol. 1997;15:3433-3440.
25. Wade PM Jr., Smith RE, Johns ME. Response of esthesioneuroblastoma to chemotherapy. Report of five cases and review of the literature. Cancer. 1984;53:1036-1041.
26. Eden BV, Debo RF, Lamer JM, et al. Esthesioneuroblastoma. Long-term outcome and patterns of failure-the University of Virginia experience. Cancer. 1994;73:2556-2562.
27. Klaassen RJ, Trebo MM, Koplewitz BZ, et al. High-risk neuroblastoma in Ontario: a report of experience from 1989 to 1995. J Pediatr Hematol Oncol. 2003;25:8-13.